Literature DB >> 26099984

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Josep M Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S Finn.   

Abstract

Entities:  

Year:  2015        PMID： 26099984     DOI： 10.1038/nrclinonc.2015.121

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  61 in total

1.  EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.

Authors:  Qiongzhu Dong; Yi Du; Hui Li; Chunxiao Liu; Yongkun Wei; Mei-Kuang Chen; Xixi Zhao; Yu-Yi Chu; Yufan Qiu; Lunxiu Qin; Hirohito Yamaguchi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2018-12-20       Impact factor: 12.701

Review 2.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

3.  Treatment of Hepatocellular Carcinoma With Lenvatinib.

Authors:  Kwang-Hyub Han
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-11

Review 4.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

Review 5.  Immune checkpoint inhibitors for hepatocellular carcinoma.

Authors:  Christopher E Jensen; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes
Journal:  Hepat Oncol       Date:  2016-06-27

Review 6.  Systemic therapy for advanced hepatocellular carcinoma: an update.

Authors:  Jasmin Radhika Desai; Sebastian Ochoa; Petra Alexandra Prins; Aiwu Ruth He
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 7.  Radiomics of hepatocellular carcinoma.

Authors:  Sara Lewis; Stefanie Hectors; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2021-01

8.  NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.

Authors:  Shuang Liang; Hsiao-Yen Ma; Zhenyu Zhong; Debanjan Dhar; Xiao Liu; Jun Xu; Yukinori Koyama; Takahiro Nishio; Daniel Karin; Gabriel Karin; Ryan Mccubbin; Cuili Zhang; Ronglin Hu; Guizhi Yang; Li Chen; Souradipta Ganguly; Tian Lan; Michael Karin; Tatiana Kisseleva; David A Brenner
Journal:  Gastroenterology       Date:  2018-11-13       Impact factor: 22.682

9.  MiR-3196, a p53-responsive microRNA, functions as a tumor suppressor in hepatocellular carcinoma by targeting FOXP4.

Authors:  Wenjing Qi; Chengshun Gao; Li Zhang; Zhenming Gao; Jidong Sui; Chuanchun Han; Deguang Sun
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 10.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.